SAR443820

TargetRIPK1

Modalitysmall molecule inhibitor

IndicationAmyotrophic lateral sclerosis

PhasePhase 2 (Terminated)

PartnerDenali

Trial IDNCT05630547

Notes

The Phase 2 HIMALAYA trial for ALS was also terminated due to lack of efficacy, though the drug demonstrated target engagement and was well tolerated.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 3, 2026